Patents by Inventor Tetsuo Kiso
Tetsuo Kiso has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11973272Abstract: A spacecraft includes: a main-reflection unit configured to reflect and emit a radio wave outside, a sub-reflection unit configured to face the main-reflection unit, a radiator arranged to face the sub-reflection unit and configured to radiate the radio wave in a direction of the sub-reflection unit, a main body configured to be able to accommodate at least one part of the sub-reflection unit therein, and a delivery device connected to the sub-reflection unit and configured to deliver the sub-reflection unit, at least one part of which is accommodated in the main body, to a position where the sub-reflection unit is able to reflect the radio wave radiated from the radiator to the main-reflection unit and cause the main-reflection unit to radiate the radio wave outside.Type: GrantFiled: April 18, 2019Date of Patent: April 30, 2024Assignee: Institute for Q-shu Pioneers of Space, Inc.Inventors: Shunsuke Onishi, Tetsuo Yasaka, Kazuo Kuno, Masahiko Uetsuhara, Yohei Koga, Shinji Ito, Yonosuke Ichiki, Kazuo Kiso, Mutsuhito Tobo
-
Patent number: 11967763Abstract: Spacecraft and antenna apparatus that can be more easily deployed from a stored state can include: a main-reflection unit including a plurality of ribs formed to be deployable in a stored state in which the ribs are folded and a sheet body provided between a plurality of the ribs and configured to be capable of reflecting a radio wave radiated from a radiator and emitting the radio wave outside, and a restriction member configured to restrict deployment of the plurality of ribs in the stored state, and release the restriction by operation of a restriction release member different from the main-reflection unit.Type: GrantFiled: April 18, 2019Date of Patent: April 23, 2024Assignee: Institute for Q-shu Pioneers of Space, Inc.Inventors: Shunsuke Onishi, Tetsuo Yasaka, Kazuo Kuno, Masahiko Uetsuhara, Yohei Koga, Shinji Ito, Yonosuke Ichiki, Kazuo Kiso, Mutsuhito Tobo
-
Publication number: 20170327474Abstract: [Problem] Provided is a pharmaceutical, in particular, a pharmaceutical composition which is useful for the treatment of pain. [Means for Solution] The present inventors have made extensive studies using model animals with pain for the purpose of providing a therapeutic agent for pain. As a result, they have found that 11?-hydroxydehydrogenase type 1 (11?-HSD1) inhibitor, in particular, a triazole compound having a cyclic group at the 3-position (or 5-position) of a triazole ring has a good effect of ameliorating chronic pain. That is, according to the present invention, a pharmaceutical composition comprising an 11?-HSD1 inhibitor, in particular, the triazole compound of the present invention, as an active ingredient, is useful for the treatment of pain (particularly, neuropathic pain or fibromyalgia).Type: ApplicationFiled: July 31, 2017Publication date: November 16, 2017Applicant: ASTELLAS PHARMA INC.Inventors: Tetsuo KISO, Mina TSUKAMOTO
-
Patent number: 9765040Abstract: [Problem] Provided is a pharmaceutical, in particular, a pharmaceutical composition which is useful for the treatment of pain. [Means for Solution] The present inventors have made extensive studies using model animals with pain for the purpose of providing a therapeutic agent for pain. As a result, they have found that 11?-hydroxydehydrogenase type 1 (11?-HSD1) inhibitor, in particular, a triazole compound having a cyclic group at the 3-position (or 5-position) of a triazole ring has a good effect of ameliorating chronic pain. That is, according to the present invention, a pharmaceutical composition comprising an 11?-HSD1 inhibitor, in particular, the triazole compound of the present invention, as an active ingredient, is useful for the treatment of pain (particularly, neuropathic pain or fibromyalgia).Type: GrantFiled: September 6, 2011Date of Patent: September 19, 2017Assignee: Astellas Pharma Inc.Inventors: Tetsuo Kiso, Mina Tsukamoto
-
Publication number: 20130165491Abstract: [Problem] Provided is a pharmaceutical, in particular, a pharmaceutical composition which is useful for the treatment of pain. [Means for Solution] The present inventors have made extensive studies using model animals with pain for the purpose of providing a therapeutic agent for pain. As a result, they have found that 11?-hydroxydehydrogenase type 1 (11?-HSD1) inhibitor, in particular, a triazole compound having a cyclic group at the 3-position (or 5-position) of a triazole ring has a good effect of ameliorating chronic pain. That is, according to the present invention, a pharmaceutical composition comprising an 11?-HSD1 inhibitor, in particular, the triazole compound of the present invention, as an active ingredient, is useful for the treatment of pain (particularly, neuropathic pain or fibromyalgia).Type: ApplicationFiled: September 6, 2010Publication date: June 27, 2013Applicant: ASTELLAS PHARMA INC.Inventors: Tetsuo Kiso, Mina Tsukamoto
-
Patent number: 8106190Abstract: To provide a novel and excellent agent for treating or preventing nociceptive pain, neuropathic pain, cancer pain, headache, bladder function disorder and the like, based on the inhibitory action on the capsaicin receptor VR1 activation. The present invention was accomplished by confirming that a benzamide derivative characterized by the possession of a benzene ring in which a single ring is condensed on the nitrogen atom of amido group and possession of a lower alkylamino or an amino group substituted with a ring group at the neighboring position of said amido group has a strong inhibitory action on VR1 activation and excellent pharmacological actions based on this and by finding that it can become an excellent agent for treating or preventing VR1-involved diseases such as nociceptive pain, neuropathic pain, cancer pain, headache, bladder function disorder and the like.Type: GrantFiled: November 29, 2006Date of Patent: January 31, 2012Assignee: Astellas Pharma Inc.Inventors: Takahiro Kuramochi, Ryoji Hirabayashi, Yohei Koganemaru, Ryosuke Munakata, Koichi Yonezawa, Tetsuo Kiso
-
Patent number: 7855198Abstract: There is provided a compound having a capsaicin receptor VR1 inhibitory activity and useful as a therapeutic agent for various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, bladder diseases including overactive bladder, and the like. A benzamide derivative or a salt thereof wherein a benzene ring is attached to a D ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring) through an amide bond, the benzene ring is directly bonded to an E ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring), and the benzene ring is further bonded to A (an amino moiety, a monocyclic or bicyclic heterocycle) through L (a lower alkylene).Type: GrantFiled: July 2, 2009Date of Patent: December 21, 2010Assignee: Astellas Pharma Inc.Inventors: Takahiro Kuramochi, Norio Asai, Kazuhiro Ikegai, Seijiro Akamatsu, Hironori Harada, Noriko Ishikawa, Shohei Shirakami, Satoshi Miyamoto, Toshihiro Watanabe, Tetsuo Kiso
-
Publication number: 20090270365Abstract: There is provided a compound having a capsaicin receptor VR1 inhibitory activity and useful as a therapeutic agent for various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, bladder diseases including overactive bladder, and the like. A benzamide derivative or a salt thereof wherein a benzene ring is attached to a D ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring) through an amide bond, the benzene ring is directly bonded to an E ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring), and the benzene ring is further bonded to A (an amino moiety, a monocyclic or bicyclic heterocycle) through L (a lower alkylene).Type: ApplicationFiled: July 2, 2009Publication date: October 29, 2009Applicant: Astellas Pharma Inc.Inventors: Takahiro KURAMOCHI, Norio ASAI, Kazuhiro IKEGAI, Seijiro AKAMATSU, Hironori HARADA, Noriko ISHIKAWA, Shohei SHIRAKAMI, Satoshi MIYAMOTO, Toshihiro WATANABE, Tetsuo KISO
-
Publication number: 20090233900Abstract: To provide a novel and excellent agent for treating or preventing nociceptive pain, neuropathic pain, cancer pain, headache, bladder function disorder and the like, based on the inhibitory action on the capsaicin receptor VR1 activation. The present invention was accomplished by confirming that a benzamide derivative characterized by the possession of a benzene ring in which a single ring is condensed on the nitrogen atom of amido group and possession of a lower alkylamino or an amino group substituted with a ring group at the neighboring position of said amido group has a strong inhibitory action on VR1 activation and excellent pharmacological actions based on this and by finding that it can become an excellent agent for treating or preventing VR1-involved diseases such as nociceptive pain, neuropathic pain, cancer pain, headache, bladder function disorder and the like.Type: ApplicationFiled: November 29, 2006Publication date: September 17, 2009Applicant: Astellas Pharma Inc.Inventors: Takahiro Kuramochi, Ryoji Hirabayashi, Yohei Koganemaru, Ryosuke Munakata, Koichi Yonezawa, Tetsuo Kiso
-
Patent number: 7585878Abstract: There is provided a compound having a capsaicin receptor VR1 inhibitory activity and useful as a therapeutic agent for various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, bladder diseases including overactive bladder, and the like. A benzamide derivative or a salt thereof wherein a benzene ring is attached to a D ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring) through an amide bond, the benzene ring is directly bonded to an E ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring), and the benzene ring is further bonded to A (an amino moiety, a monocyclic or bicyclic heterocycle) through L (a lower alkylene).Type: GrantFiled: June 10, 2004Date of Patent: September 8, 2009Assignee: Astellas Pharma Inc.Inventors: Takahiro Kuramochi, Norio Asai, Kazuhiro Ikegai, Seijiro Akamatsu, Hironori Harada, Noriko Ishikawa, Shohei Shirakami, Satoshi Miyamoto, Toshihiro Watanabe, Tetsuo Kiso
-
Publication number: 20070167444Abstract: There is provided a compound having a capsaicin receptor VR1 inhibitory activity and useful as a therapeutic agent for various pains including inflammatory pain and neurogenic pain, migraine, cluster headache, bladder diseases including overactive bladder, and the like. A benzamide derivative or a salt thereof wherein a benzene ring is attached to a D ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring) through an amide bond, the benzene ring is directly bonded to an E ring (a monocyclic or bicyclic hydrocarbon ring or a monocyclic or bicyclic heteroaromatic ring), and the benzene ring is further bonded to A (an amino moiety, a monocyclic or bicyclic heterocycle) through L (a lower alkylene).Type: ApplicationFiled: June 10, 2004Publication date: July 19, 2007Inventors: Takahiro Kuramochi, Norio Asai, Kazuhiro Ikegai, Seijiro Akamatsu, Hironori Harada, Noriko Ishikawa, Shohei Shirakami, Satoshi Miyamoto, Toshihiro Watanabe, Tetsuo Kiso
-
Publication number: 20040087608Abstract: This invention relates to pharmaceuticals for neuropathic pains comprising an mGluR1 receptor antagonist for systemic administration. Drugs efficacious in treating various neuropathic pain can be provided by the invention.Type: ApplicationFiled: June 26, 2003Publication date: May 6, 2004Applicant: YAMANOUCHI PHARMACEUTICAL CO., LTD.Inventors: Masamichi Okada, Yukinori Nagakura, Tetsuo Kiso, Takashi Toya, Satoshi Hayashibe
-
Patent number: 6664283Abstract: This invention relates to pharmaceuticals for neuropathic pains comprising an mGluR1 receptor antagonist for systemic administration. Drugs efficacious in treating various neuropathic pain can be provided by the invention.Type: GrantFiled: May 15, 2002Date of Patent: December 16, 2003Assignee: Yamanouchi Pharmaceutical Co., Ltd.Inventors: Masamichi Okada, Yukinori Nagakura, Tetsuo Kiso, Takashi Toya, Satoshi Hayashibe